Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: health

Nearly 10% of global GDP is spent on health care, according to the latest data from the WHO. Rich countries spend an average of 12%, with America an outlier well above that; middle-income ones (including China) 6%; and low-income ones just under 6%. In developed countries, 60% of health spending comes from public sources. In poor economies the figure is around 40%. As economies grow and governments are able to allocate more resources to health, the share of individual out-of-pocket spending typically falls. But the variation in such spending in poor countries suggests that the health systems they end up with depend on their choice of public policies.

IN 2013 A GROUP of doctors and health economists argued in the Lancet that a “grand convergence” would be possible over the next two decades. If governments spent more on health, and more wisely, mortality rates in the poorest countries could fall to those seen in the healthiest middle-income ones. That would amount to saving 10m lives a year.

To see what a high-quality health-care system in a developing country looks like, consider the case of Farida Waree, a 55-year-old housewife in Thailand. In early 2016 Mrs Waree felt a lump on her right breast. She went to her local primary-care centre, which referred her to Nakornayok provincial hospital. She was diagnosed with cancer, and over the next year was given a mastectomy, chemotherapy and Herceptin, an anti-cancer drug. Five years earlier her treatment might have cost her 800,000 baht (about $25,000), much more than she and her family could have afforded. Instead, nearly all the costs were covered under Thailand’s Universal Coverage Scheme. The cancer is now in remission. “I consider myself very fortunate,” she says.

Get our daily newsletter

Upgrade your inbox and get our Daily Dispatch and Editor’s Picks.

Read more

A pair of new spacecraft that will observe our planet’s ever-changing water cycle, ice sheets and crust is in final preparations for a California launch no earlier than Saturday, May 19. The Gravity Recovery and Climate Experiment Follow-On (GRACE-FO) mission, a partnership between NASA and the German Research Centre for Geosciences (GFZ), will take over where the first GRACE mission left off when it completed its 15-year mission in 2017.

GRACE-FO will continue monitoring monthly changes in the distribution of mass within and among Earth’s atmosphere, oceans, land and ice sheets, as well as within the solid Earth itself. These data will provide unique insights into Earth’s changing climate, Earth system processes and even the impacts of some human activities, and will have far-reaching benefits to society, such as improving water resource management.

“Water is critical to every aspect of life on Earth—for health, for agriculture, for maintaining our way of living,” said Michael Watkins, GRACE-FO science lead and director of NASA’s Jet Propulsion Laboratory in Pasadena, California. “You can’t manage it well until you can measure it. GRACE-FO provides a unique way to measure water in many of its phases, allowing us to manage water resources more effectively.”

Read more

Not surprising and yet fascinating to actually see — “The researchers found that music activates the brain, causing whole regions to communicate. By listening to the personal soundtrack, the visual network, the salience network, the executive network and the cerebellar and corticocerebellar network pairs all showed significantly higher functional connectivity.”

“Ever get chills lis­ten­ing to a par­tic­u­lar­ly mov­ing piece of music? You can thank the salience net­work of the brain for that emo­tion­al joint. Sur­pris­ing­ly, this region also remains an island of remem­brance that is spared from the rav­ages of Alzheimer’s dis­ease. Researchers at the Uni­ver­si­ty of Utah Health are look­ing to this region of the brain to devel­op music-based treat­ments to help alle­vi­ate anx­i­ety in patients with demen­tia. Their research will appear in the April online issue of The Jour­nal of Pre­ven­tion of Alzheimer’s Disease…

Read more

Whole genome sequencing is more precise than other methods, and it just keeps getting faster and cheaper. Joel Sevinsky, head of the Molecular Science Laboratory at the Colorado Department of Public Health and Environment (CDPHE), told the Associated Press his lab can sequence the genome of a suspected pathogen in less than 72 hours.

Whole genome sequencing is already helping researchers address food-borne outbreaks, including a 2017 salmonella outbreak that stretched across 21 states, and the current romaine outbreak.

It’s even identifying contaminated food before it even reaches the public. According to the AP, inspectors used genome sequencing to find pathogens that could have caused outbreaks when they inspected food plants. They were able to recall the tainted products before they ever reached grocery stores or restaurants, preventing countless people from being sickened.

Read more

This month I’m participating in Cato Institute’s Cato Unbound discussion. Cato is one of the world’s leading think tanks. Here’s my new and second essay for the project:

Professor David D. Friedman sweeps aside my belief that religion may well dictate the development of AI and other radical transhumanist tech in the future. However, at the core of a broad swath of American society lies a fearful luddite tradition. Americans—including the U.S. Congress, where every member is religious—often base their life philosophies and work ethics on their faiths. Furthermore, a recent Pew study showed 7 in 10 Americans were worried about technology in people’s bodies and brains, even if it offered health benefits.

It rarely matters what point in American history innovation has come out. Anesthesia, vaccines, stem cells, and other breakthroughs have historically all battled to survive under pressure from conservatives and Christians. I believe that if formal religion had not impeded our natural secular progress as a nation over the last 250 years, we would have been much further along in terms of human evolution. Instead of discussing and arguing about our coming transhumanist future, we’d be living in it.

Our modern-day battle with genetic editing and whether our government will allow unhindered research of it is proof we are still somewhere between the Stone Age and the AI Age. Thankfully, China and Russia are forcing the issue, since one thing worse than denying Americans their religion is denying them the right to claim the United States is the greatest, most powerful nation in the world.

A general theme of government regulation in American science is to rescind red tape and avoid religious disagreement when deemed necessary to remain the strongest nation. As unwritten national policy, we broadly don’t engage science to change the human species for the better. If you doubt this, just try to remember the science topics discussed between Trump and Clinton in the last televised presidential debates. Don’t remember any? No one else does either, because mainstream politicians regretfully don’t talk about science or take it seriously.

Read more

A new biotech company co-founded by CRISPR pioneer Jennifer Doudna is developing a device that uses CRISPR to detect all kinds of diseases like malaria, tuberculosis, and Zika. The tech is still just in prototype phase, but research in the field is showing promising results. These CRISPR-based diagnostic tools have the potential to revolutionize how we test for diseases in the hospital, or even at home.

Called Mammoth Biosciences, the company is working on a credit card-sized paper test and smartphone app combo for disease detection. But the applications extend beyond that: The same technology could be used in agriculture, to determine what’s making animals sick or what sorts of microbes are found in soil, or even in the oil and gas industry, to detect corrosive microbes in pipelines, says Trevor Martin, the CEO of Mammoth Biosciences, who holds a PhD in biology from Stanford University. The company is focusing on human health applications first, however.

Read more

Wilmington, DE, April 19, 2018 — Scientists at Christiana Care Health System’s Gene Editing Institute have developed a potentially breakthrough CRISPR gene-editing tool. It could allow researchers to take fragments of DNA extracted from human cells, put them into a test tube, and quickly and precisely engineer multiple changes to the genetic code, according to a new study published today in the CRISPR Journal.

Investigators at the Gene Editing Institute, which is part of the Helen F. Graham Cancer Center & Research Institute at Christiana Care, said their new “cell-free” CRISPR technology is the first CRISPR tool capable of making multiple edits to DNA samples “in vitro,” which means in a test tube or petri dish. The advance could have immediate value as a diagnostic tool, replicating the exact genetic mutations found in the tumors of individual cancer patients. Mutations that cause cancer to spread can differ from patient to patient, and being able to quickly identify the correct mutation affecting an individual patient can allow clinicians to implement a more targeted treatment strategy.

“With this new advance, we should be able to work with laboratory cultures and accomplish gene edits in less than a day, significantly reducing the time required for diagnostics compared to other CRISPR tools, and with much greater precision,” said Eric Kmiec, Ph.D., director of the Gene Editing Institute and principal author of the study. “This is particularly important for diagnostics linked to cancer care where time is critical.”

Read more

A UK man who caught what was dubbed the world’s “worst-ever” case of super-gonorrhoea has been cured, Public Health England (PHE) said — but two similar cases have been reported in Australia.

The unidentified heterosexual man, who had a partner in the UK, picked up the infection having sex with another woman in South-East Asia, PHE said.

Health officials said it was the first time the infection could not be cured with the regular treatment — a combination of antibiotics azithromycin and ceftriaxone.

Read more